Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.10.0.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Revenue from contract with customer $ 264,000   $ 265,000    
Grant and other revenue 277,753 $ 511,599 553,403 $ 1,091,629  
Revenue 542,127 611,599 818,572 1,191,629  
Cost of revenue 35,392 35,710  
Research and development expenses 1,142,718 1,185,874 2,141,674 1,891,148  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,751,888 4,179,045 3,490,273 7,124,689  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,511 70,539 75,498 147,329  
Loss from operations [3] (2,425,382) (4,823,859) (4,924,583) (7,971,537)  
Other expense (20,719) [4] 40,848 (4,259,480) [4] (1,130,261) [4]  
Income tax benefit (expense) 10,929 1,631,234 10,929 3,085,406  
Net loss from continuing operations (2,435,172) (3,151,777) (9,173,134) (6,016,392)  
Loss from discontinued operations (1,938) (82,376) (1,938) (338,237)  
Gain on sale of discontinued operations, net of tax 43,053 (1,953,378) 43,053 86,748,123  
Net income (loss) (2,394,057) (5,187,531) (9,132,019) 80,393,494  
Total assets, net of depreciation and amortization 8,660,492   8,660,492   $ 20,781,436
Capital expenditures 3,165 8,170 3,165 8,170  
Other income (20,719) [4] 40,848 (4,259,480) [4] (1,130,261) [4]  
Net (loss) income from continuing operations (2,435,172) (3,151,777) (9,173,134) (6,016,392)  
Income tax benefit (expense) 10,929 1,631,234 10,929 3,085,406  
UNITED STATES          
Total assets, net of depreciation and amortization 8,636,954 25,801,110 8,636,954 25,801,110  
Non-US [Member]          
Total assets, net of depreciation and amortization 23,538 101,105 23,538 101,105  
Royalty [Member]          
Revenue from contract with customer 6,665 7,460  
License [Member]          
Revenue from contract with customer 257,709 100,000 257,709 100,000  
Diagnostics Segment [Member]          
Grant and other revenue 156,889 418,375 389,325 989,737  
Revenue 421,263 518,375 654,494 1,089,737  
Cost of revenue 35,392   35,710  
Research and development expenses 913,158 1,108,101 1,698,169 1,521,303  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (527,287) (589,726) (1,079,385) (431,566)  
Other expense [4] [4] [4]  
Income tax benefit (expense) 2,356 201,125 1,284 146,296  
Net loss from continuing operations (524,931) (388,601) (1,078,101) (285,270)  
Loss from discontinued operations (1,938) (82,376) (1,938) (338,237)  
Gain on sale of discontinued operations, net of tax 43,053 (1,953,378) 43,053 86,748,123  
Net income (loss) (483,816) (2,424,355) (1,036,986) 86,124,616  
Capital expenditures  
Other income [4] [4] [4]  
Net (loss) income from continuing operations (524,931) (388,601) (1,078,101) (285,270)  
Income tax benefit (expense) 2,356 201,125 1,284 146,296  
Diagnostics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 409,769 16,373,919 409,769 16,373,919  
Diagnostics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 22,147 98,806 22,147 98,806  
Diagnostics Segment [Member] | Royalty [Member]          
Revenue from contract with customer 6,665 7,460  
Diagnostics Segment [Member] | License [Member]          
Revenue from contract with customer 257,709 100,000 257,709 100,000  
Therapeutics Segment [Member]          
Grant and other revenue 120,864 93,224 164,078 101,892  
Revenue 120,864 93,224 164,078 101,892  
Cost of revenue    
Research and development expenses 229,560 77,773 443,505 369,845  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 16,630 3,462 25,237 5,983  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (125,326) 11,989 (304,664) (273,936)  
Other expense [4] [4] [4]  
Income tax benefit (expense) 560 (4,089) 363 92,861  
Net loss from continuing operations (124,766) 7,900 (304,301) (181,075)  
Loss from discontinued operations  
Gain on sale of discontinued operations, net of tax  
Net income (loss) (124,766) 7,900 (304,301) (181,075)  
Capital expenditures  
Other income [4] [4] [4]  
Net (loss) income from continuing operations (124,766) 7,900 (304,301) (181,075)  
Income tax benefit (expense) 560 (4,089) 363 92,861  
Therapeutics Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 87,751 16,002 87,751 16,002  
Therapeutics Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization  
Therapeutics Segment [Member] | Royalty [Member]          
Revenue from contract with customer  
Therapeutics Segment [Member] | License [Member]          
Revenue from contract with customer  
Corporate Segment [Member]          
Grant and other revenue  
Revenue  
Cost of revenue    
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,735,258 4,175,583 3,465,036 7,118,706  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,511 70,539 75,498 147,329  
Loss from operations [3] (1,772,769) (4,246,122) (3,540,534) (7,266,035)  
Other expense (20,719) [4] 40,848 (4,259,480) [4] (1,130,261) [4]  
Income tax benefit (expense) 8,013 1,434,198 9,282 2,846,249  
Net loss from continuing operations (1,785,475) (2,771,076) (7,790,732) (5,550,047)  
Loss from discontinued operations  
Gain on sale of discontinued operations, net of tax  
Net income (loss) (1,785,475) (2,771,076) (7,790,732) (5,550,047)  
Capital expenditures 3,165 8,170 3,165 8,170  
Other income (20,719) [4] 40,848 (4,259,480) [4] (1,130,261) [4]  
Net (loss) income from continuing operations (1,785,475) (2,771,076) (7,790,732) (5,550,047)  
Income tax benefit (expense) 8,013 1,434,198 9,282 2,846,249  
Corporate Segment [Member] | UNITED STATES          
Total assets, net of depreciation and amortization 8,139,434 9,411,189 8,139,434 9,411,189  
Corporate Segment [Member] | Non-US [Member]          
Total assets, net of depreciation and amortization 1,391 2,299 1,391 2,299  
Corporate Segment [Member] | Royalty [Member]          
Revenue from contract with customer  
Corporate Segment [Member] | License [Member]          
Revenue from contract with customer  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($37,511 and $70,539 for the three-month periods ended June 30, 2018 and 2017, and $75,498 and $147,329 for the six-month periods ended June 30, 2018 and 2017, respectively).
[3] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.